Parallel imports
Parallel import of medicines allows us to purchase medicines that are identical or sufficiently similar to medicines registered in Lithuania from other EU countries where prices are lower, and then distribute them in our country. A parallel-imported medicine is considered sufficiently similar to a medicinal product registered in the Republic of Lithuania if it meets the following criteria: the same active substance, the same strength, the same pharmaceutical form and route of administration, and the same clinical characteristics. Parallel imported medicinal products shall be registered and parallel import authorizations shall be issued by the State Medicines Control Authority.
Parallel importation of medicines benefits not only wholesalers, but also consumers, who have access to much cheaper medicines. In addition, parallel import of medicines also helps to reduce the risk of supply disruptions, and in the event of a shortage of medicines, parallel imports can effectively contribute to solving this problem. In other words, we contribute to ensuring that consumers have access to the same medicines at a lower price than the normal market price and that there is no shortage of the medicines they need. Parallel imports promote competitiveness and help people to save a significant amount of money on their treatment costs.
The company is a member of the Parallel Medicines Import Association (LVIA).
You can find out more about parallel imports at www.lygiagretusimportas.lt
